Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Helsinn Investment Fund S.A., SICAR, is a corporate venture capital fund established by the Swiss pharmaceutical company Helsinn Group. Launched in 2016 with an initial commitment of $50 million, the fund focuses on early-stage investment opportunities in areas of high unmet patient need. It aims to support companies developing innovative technologies and assets in cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions. The fund provides scientific and clinical strategy guidance, operational and board support alongside financial investment. It was rebranded as 3B Future Health Ventures.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Helsinn Investment Fund's primary investment focus?
- Helsinn Investment Fund primarily focuses on the Health Tech & Life Sciences sector, with its sole disclosed portfolio company, Fore Biotherapeutics, operating in this area.
- What is the most recent investment made by Helsinn Investment Fund?
- Helsinn Investment Fund participated in a Debt Financing round for Fore Biotherapeutics (formerly NovellusDx) in April 2018.
- Can you name a notable portfolio company of Helsinn Investment Fund?
- A notable portfolio company of Helsinn Investment Fund is Fore Biotherapeutics, which focuses on precision oncology treatments.
- What is the typical investment range for Helsinn Investment Fund?
- Helsinn Investment Fund's investment range is stated as $6M - $6M.
- Where is Helsinn Investment Fund headquartered?
- Helsinn Investment Fund is headquartered in Luxembourg.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Legal name | Helsinn Investment Fund S.A., SICAR |
|---|---|
| Founded | 2016-10 |